Statistik Asas
| LEI | 549300NGS2FJGGDBGS06 |
| CIK | 1612940 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ProQR Therapeutics N.V.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position at June 30, 2025 and December 31, 2024 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three and Six Month Periods ended June 30, 2025 and 2024 2 Unaudited Co |
|
| August 7, 2025 |
Exhibit 99.2 ProQR Announces Second Quarter 2025 Operating and Financial Results ● Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseases ● Advancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett Syndrome ● Hosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 Phase 1 trial design and 2025 data expectations, p |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 7, 2025 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Including Area Code, |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Including |
|
| June 26, 2025 |
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP Exhibit 99.1 ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP ● First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025 ● Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA editing platform into clinical devel |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Including |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 8, 2025 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Including Area Code, of |
|
| May 8, 2025 |
Attributable to owners of the Company Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position at March 31, 2025 and December 31, 2024 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three Month Periods ended March 31, 2025 and 2024 2 Unaudited Condense |
|
| May 8, 2025 |
Attributable to owners of the Company Exhibit 99.2 ProQR Announces First Quarter 2025 Operating and Financial Results ● Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases ● Strengthened leadership with appointments of Chief Financial Officer and Chief Medical Officer ● € 132.4 million cash and cash eq |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Including |
|
| May 1, 2025 |
Exhibit 99.2 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. - NOTICE AND AGENDA ProQR Therapeutics N.V. | Zernikedreef 9 | 2333 CK Leiden | The Netherlands | +31 88 166 7000 | www.proqr.com Page 2 / 3 2025 Annual General Meeting of Shareholders ProQR Therapeutics N.V. – Notice and Agenda Notice for the AGM The 2025 annual general meeting of shareholders of ProQR Therapeutics N |
|
| May 1, 2025 |
POWER OF ATTORNEY AGM PROQR THERAPEUTICS N.V. JUNE 3, 2025 Exhibit 99.4 POWER OF ATTORNEY AGM PROQR THERAPEUTICS N.V. JUNE 3, 2025 Note: If you hold your shares through a bank, a financial institution, or other financial intermediary, you are considered a "beneficial owner" and you should follow the instructions and use the voting instrument provided by the bank or intermediary, financial institution, account holder or other financial intermediary that ho |
|
| May 1, 2025 |
Exhibit 99.3 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. Explanatory Notes to the Agenda ProQR Therapeutics N.V. | Zernikedreef 9 | 2333 CK Leiden | The Netherlands | +31 88 166 7000 | www.proqr.com Page 2 / 7 2025 Annual General Meeting of Shareholders ProQR Therapeutics N.V. - Explanatory Notes to the Agenda Explanatory notes to the agenda for the 2025 annual general meet |
|
| May 1, 2025 |
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 Exhibit 99.1 ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 LEIDEN, Netherlands & CAMBRIDGE, Mass., May 1, 2025 – ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| April 14, 2025 |
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth Exhibit 99.1 ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 – ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dennis Hom a |
|
| March 25, 2025 |
Up to 3,523,538 Ordinary Shares Offered by the Selling Shareholder TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-285767 PROSPECTUS Up to 3,523,538 Ordinary Shares Offered by the Selling Shareholder This prospectus relates to the proposed resale or other disposition, from time to time, in one or more offerings, of up to 3,523,538 ordinary shares, nominal value €0.04 per share (the “Shares”), by the selling shareholder identified in this |
|
| March 21, 2025 |
VIA EDGAR March 21, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| March 13, 2025 |
Exhibit 4.6 INDEMNIFICATION AGREEMENT [●] BETWEEN PROQR THERAPEUTICS N.V. the Company [●] the Indemnitee Allen Overy Shearman Sterling LLP Contents Clause Page 1. Definitions and Interpretation 2 2. Indemnification 3 3. Advancement of Expenses 4 4. Determination of Entitlement to and Payment of Indemnification 5 5. Notification and Defense of Proceedings 6 6. Liability Insurance 7 7. Non-Exclusivi |
|
| March 13, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Daniel de Boer, certify that: 1. I have reviewed this annual report on Form 20-F of ProQR Therapeutics N.V. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the st |
|
| March 13, 2025 |
Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 Of The Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Daniel de Boer, the Chief Executive Officer, and Jurriaan Dekkers, the Chief Financial Officer, of ProQR Therapeutics N.V. (the “Company”), hereby certify, that, |
|
| March 13, 2025 |
As filed with the Securities and Exchange Commission on March 13, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 13, 2025 Registration No. |
|
| March 13, 2025 |
ADDENDUM TO THE CALL OPTION AGREEMENT Exhibit 4.4 ADDENDUM TO THE CALL OPTION AGREEMENT THIS ADDENDUM IS MADE ON 6 NOVEMBER 2018 BETWEEN (1) ProQR Therapeutics N.V., a public company under Dutch law (naamloze vennootschap), having its official seat in Leiden, its office address at Zernikedreef 9, 2333 CK Leiden, the Netherlands and registered in the Dutch Commercial Register under number 54600790 (the Company); (2) Stichting Continuit |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF T |
|
| March 13, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ProQR Therapeutics N. |
|
| March 13, 2025 |
Exhibit 4.16 DESCRIPTION OF THE REGISTRANT’S SECURITIES PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The ordinary shares, nominal value €0.04 per share (“Ordinary Shares”), of ProQR Therapeutics N.V. (the “Company,” “we,” “us,” and “our”), is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following description s |
|
| March 13, 2025 |
PROQR THERAPEUTICS N.V. GROUP SECURITIES TRADING POLICY Exhibit 11.1 PROQR THERAPEUTICS N.V. GROUP SECURITIES TRADING POLICY 1. Summary The Securities Trading Policy contains the rules for trading in shares of ProQR Therapeutics N.V. and any type of Financial Instruments (for definitions see the policy) related thereto, which includes options. In short, you are not allowed to trade with ProQR shares or related Financial Instruments when you are in the |
|
| March 13, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jurriaan Dekkers, certify that: 1. I have reviewed this annual report on Form 20-F of ProQR Therapeutics N.V. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| March 13, 2025 |
ProQR Announces Year End 2024 Operating and Financial Results Exhibit 99.1 ProQR Announces Year End 2024 Operating and Financial Results · Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases · Company expects up to four clinical data readouts in 2025 and 2026 across multiple programs, highlighted by first clinical data for AX |
|
| March 13, 2025 |
Exhibit 4.1 The Terms and Conditions of the ProQR Therapeutics N.V. Equity Incentive Plan Revised version (V.3) dated 22 May 2024 Rule 1 Definitions In the Rules of this Plan, unless the context otherwise requires, the following words and expressions shall have the meanings as set out below: Articles of Association the articles of association of the Company as amended from time to time; Business D |
|
| March 13, 2025 |
Exhibit 1.1 ARTICLES OF ASSOCIATION DEFINITIONS AND INTERPRETATION Article 1 1.1 In these articles of association the following definitions shall apply: Article An article of these articles of association. Board Board Rules CEO The Company’s board of directors. The internal rules applicable to the Board. The Company’s chief executive officer. Class Meeting The meeting of holders of shares of a cer |
|
| March 13, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the registration statements No. 333-260801 and No. 333-199451 on Form S-8 and the registration statements No. 333-270943, No. 333-263166, No. 333-248740, and No. 333-282419 on Form F-3 of our reports dated March 13, 2025, with respect to the consolidated financial statements of Pro |
|
| March 13, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 13, 2025 As filed with the U.S. Securities and Exchange Commission on March 13, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROQR THERAPEUTICS N.V. (Exact name of registrant as specified in its charter) The Netherlands Not applicable (State or other jurisdiction of incorporation or organi |
|
| March 13, 2025 |
ADDENDUM TO THE CALL OPTION AGREEMENT Exhibit 4.5 ADDENDUM TO THE CALL OPTION AGREEMENT THIS ADDENDUM IS MADE ON 27 FEBRUARY 2025 BETWEEN (1) ProQR Therapeutics N.V., a public company under Dutch law (naamloze vennootschap), having its official seat in Leiden, its office address at Zernikedreef 9, 2333 CK Leiden, the Netherlands and registered in the Dutch Commercial Register under number 54600790 (the Company); (2) Stichting Continui |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| March 13, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) ProQR Therapeutics N. |
|
| February 14, 2025 |
EX-99.1 2 tm256516d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but no |
|
| February 12, 2025 |
PRQR / ProQR Therapeutics N.V. / Adage Capital Management, L.P. - JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The unders |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Inc |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Inclu |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Inclu |
|
| December 11, 2024 |
Exhibit 99.1 INVESTOR & ANALYST EVENT December 11, 2024 1. Welcome & Agenda Sarah Kiely 2. Strategy overview Daniel A. de Boer 3. Axiomer Platform Peter Beal, PhD 4. AX -0810 for Cholestatic Diseases Prof. Gideon Hirschfield, MA, MB Bchir, FRCP, PhD Gerard Platenburg 5. AX -2402 for Rett Syndrome Monica Coenraads, MBA Gerard Platenburg ProQR Therapeutics – Investor and Analyst Event 2024 2 Agenda |
|
| December 11, 2024 |
Exhibit 99.1 ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration LEIDEN, Netherlands & CAMBRIDGE, Mass., December 11, 2024 – ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today annou |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Inclu |
|
| December 10, 2024 |
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist Exhibit 99.1 ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist LEIDEN, Netherlands & CAMBRIDGE, Mass., December 10, 2024 – ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Inclu |
|
| December 5, 2024 |
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 Exhibit 99.1 ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 LEIDEN, Netherlands & CAMBRIDGE, Mass., December 5, 2024 – ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:0 |
|
| November 7, 2024 |
Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position at September 30, 2024 and December 31, 2023 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three and Nine Month Periods ended September 30, 2024 and 2023 2 U |
|
| November 7, 2024 |
Exhibit 99.2 ProQR Announces Third Quarter 2024 Operating and Financial Results ● AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic ● Company to host virtual Investor and Analyst Event in December to highlight translational data and clinical plans for AX-0810, as well as AX-1412, targeting B4GALT1 for cardiovascular diseases, and pro |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 7, 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Including Area Code |
|
| October 25, 2024 |
Exhibit 10.1 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is entered into as of October 22, 2024 (the “Execution Date”), by and between ProQR Therapeutics N.V., a public company with limited liability (naamloze vennootschap) incorporated under the laws of The Netherlands (“ProQR”), and Eli Lilly and Company, a corporation organized and existing under the laws of Indian |
|
| October 25, 2024 |
Exhibit 1.1 ProQR Therapeutics N.V. 18,000,000 Ordinary Shares UNDERWRITING AGREEMENT Dated: October 22, 2024 ProQR Therapeutics N.V. 18,000,000 Ordinary Shares UNDERWRITING AGREEMENT October 22, 2024 Evercore Group L.L.C. Cantor Fitzgerald & Co. As Representatives of the several Underwriters, c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 c/o Cantor Fitzgerald & Co. 110 Ea |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Including Area Code, of |
|
| October 25, 2024 |
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares Exhibit 99.1 ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares LEIDEN, Netherlands & CAMBRIDGE, Mass., October 22, 2024 - ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it has commenced an underwritten public of |
|
| October 25, 2024 |
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement Exhibit 99.2 ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement LEIDEN, Netherlands and CAMBRIDGE, Mass., October 22, 2024 - ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of its previously a |
|
| October 24, 2024 |
18,000,000 Shares Ordinary Shares TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-282419 PROSPECTUS SUPPLEMENT (To Prospectus Dated October 10, 2024) 18,000,000 Shares Ordinary Shares We are selling 18,000,000 ordinary shares, with a nominal value of €0.04 per share, in this offering. We have granted the underwriters an option to purchase up to an additional 2,700,000 ordinary shares, at the public offeri |
|
| October 23, 2024 |
SUBJECT TO COMPLETION, DATED OCTOBER 22, 2024 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| October 10, 2024 |
Up to $75,000,000 Ordinary Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-282419 PROSPECTUS Up to $75,000,000 Ordinary Shares We have previously entered into a Controlled Equity OfferingSM Sales Agreement, dated November 4, 2021 (the “sales agreement”), with Cantor Fitzgerald & Co. (“Cantor” or the “Agent”), relating to the sale of our ordinary shares, nominal value €0.04 per share, offered by thi |
|
| October 8, 2024 |
VIA EDGAR October 8, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 30, 2024 |
PROQR THERAPEUTICS N.V. Ordinary Shares (nominal value €0.04 per share) Sales Agreement Exhibit 1.2 PROQR THERAPEUTICS N.V. Ordinary Shares (nominal value €0.04 per share) Sales Agreement November 4, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: ProQR Therapeutics N.V., a Dutch public company with limited liability (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1. I |
|
| September 30, 2024 |
Exhibit 5.3 To ProQR Therapeutics N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Allen Overy Shearman Sterling LLP Apollolaan 15 1077 AB Amsterdam The Netherlands PO Box 75440 1070 AK Amsterdam The Netherlands Tel +31 20 674 1000 Fax +31 20 674 1111 Amsterdam, 30 September 2024 Subject Our ref 5.3 Dutch law legal opinion 0117407-0000001 EUO3: 2016647083.5 Dear Sirs, Madam, 1. We have acted a |
|
| September 30, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) ProQR Therapeutics N. |
|
| September 30, 2024 |
As filed with the Securities and Exchange Commission on September 30, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 30, 2024 Registration No. |
|
| August 8, 2024 |
Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position at June 30, 2024 and December 31, 2023 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three and Six Month Periods ended June 30, 2024 and 2023 2 Unaudited Co |
|
| August 8, 2024 |
Exhibit 99.2 ProQR Announces Second Quarter 2024 Operating and Financial Results ● AX-0810 program targeting NTCP for cholestatic diseases and AX-1412 program targeting B4GALT1 for cardiovascular diseases advancing to the clinic in late 2024/early 2025 with translational data and trial design details to be announced in H2 2024 ● $4.5 million in milestones achieved in H1 related to progress in the |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 8, 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Including Area Code, |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Including |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 9, 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Including Area Code, of |
|
| May 9, 2024 |
Attributable to owners of the Company Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position at March 31, 2024 and December 31, 2023 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three Month Periods ended March 31, 2024 and 2023 2 Unaudited Condense |
|
| May 9, 2024 |
Attributable to owners of the Company Exhibit 99.2 ProQR Announces First Quarter 2024 Operating and Financial Results ● Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight data ● Martin Maier, PhD nominated to Board with Annual General Meeting scheduled for May 22, 2024 ● Continued strengt |
|
| May 8, 2024 |
Exhibit 99.1 ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases · ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides · Preclinical proof of concept for t |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Including |
|
| April 23, 2024 |
2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. Exhibit 99.3 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. Explanatory Notes to the Agenda ProQR Therapeutics N.V. | Zernikedreef 9 | 2333 CK Leiden | The Netherlands | +31 88 166 7000 | www.proqr.com Page 2 / 9 2024 Annual General Meeting of Shareholders ProQR Therapeutics N.V. - Explanatory Notes to the Agenda Explanatory notes to the agenda for the 2024 annual general meet |
|
| April 23, 2024 |
Exhibit 99.1 ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024 LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 – ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual Ge |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| April 23, 2024 |
2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. – NOTICE AND AGENDA Exhibit 99.2 PAGE 1 / 3 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. – NOTICE AND AGENDA 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. - NOTICE AND AGENDA PROQR THERAPEUTICS | ZERNIKEDREEF 9 | 2333 CK LEIDEN | THE NETHERLANDS | +31 88 166 7000 | WWW.PROQR.COM PAGE 2 / 3 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. – NOTICE AND AGE |
|
| April 23, 2024 |
POWER OF ATTORNEY AGM PROQR THERAPEUTICS N.V. MAY 22, 2024 Exhibit 99.4 POWER OF ATTORNEY AGM PROQR THERAPEUTICS N.V. MAY 22, 2024 Note: If you hold your shares through a bank, a financial institution, or other financial intermediary, you are considered a "beneficial owner" and you should follow the instructions and use the voting instrument provided by the bank or intermediary, financial institution, account holder or other financial intermediary that ho |
|
| April 19, 2024 |
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio Exhibit 99.1 ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 – ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA edi |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| March 13, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jurriaan Dekkers, certify that: 1. I have reviewed this annual report on Form 20-F of ProQR Therapeutics N.V. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| March 13, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the registration statements No.333-260801 and No. 333-199451 on Form S-8, and registration statements No. 333-270943, No. 333-263166, No. 333-260775, and No. 333-248740 on Form F-3 of our report dated March 13, 2024, with respect to the consolidated financial statements of ProQR Th |
|
| March 13, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Daniel de Boer, certify that: 1. I have reviewed this annual report on Form 20-F of ProQR Therapeutics N.V. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the st |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF T |
|
| March 13, 2024 |
ProQR Announces Year End 2023 Operating and Financial Results Exhibit 99.1 ProQR Announces Year End 2023 Operating and Financial Results • Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinic • Accelerated development of Axiomer™ for CNS applications via new research partnership with Rett |
|
| March 13, 2024 |
Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 Of The Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Daniel de Boer, the Chief Executive Officer, and Jurriaan Dekkers, the Chief Financial Officer, of ProQR Therapeutics N.V. (the “Company”), hereby certify, that, |
|
| March 13, 2024 |
PROQR THERAPEUTICS N.V. COMPENSATION RECOVERY POLICY Adopted as of November 14, 2023 Exhibit 97.1 PROQR THERAPEUTICS N.V. COMPENSATION RECOVERY POLICY Adopted as of November 14, 2023 ProQR Therapeutics N.V., a public limited liability company incorporated under the laws of the Netherlands (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall re |
|
| February 15, 2024 |
ProQR Announces Japanese Axiomer Exhibit 99.1 ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, Mass., February 15, 2024 – ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against an opposition filed i |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Inclu |
|
| February 14, 2024 |
PRQR / ProQR Therapeutics N.V. / VAN HERK INVESTMENTS B.V. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ProQR Therapeutics N.V. (Name of Issuer) Ordinary Shares, nominal value €0.04 per share (Title of Class of Securities) N71542109 (CUSIP Number) February 9, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 14, 2024 |
EX-99.1 2 tm245614d2ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but no |
|
| February 9, 2024 |
EX-99.1 2 tm245610d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but no |
|
| February 9, 2024 |
PRQR / ProQR Therapeutics N.V. / VAN HERK INVESTMENTS B.V. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ProQR Therapeutics N.V. (Name of Issuer) Ordinary Shares, nominal value €0.04 per share (Title of Class of Securities) N71542109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| January 19, 2024 |
Exhibit 99.1 ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 · Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and mice · Functional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzy |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includ |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includ |
|
| January 5, 2024 |
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration Exhibit 99.1 ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration · Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndrome · Collaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases LEIDEN, Netherlands & CAMBRIDGE |
|
| December 8, 2023 |
Exhibit 99.1 ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome Agreement provides ProQR with initial payment of €8M and up to €165M in earn-out payments, as well as potential double- |
|
| December 8, 2023 |
Amended and Restated Asset Purchase AGREEMENT dated 7 DECEMBER 2023 Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Amended and Restated Asset Purchase AGREEMENT dated 7 DECEMBER 2023 by and between PROQR THERAPEUTICS I B.V. PROQR THERAPEUTICS |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Inclu |
|
| November 7, 2023 |
Exhibit 99.2 ProQR Announces Third Quarter 2023 Operating and Financial Results ● Continued advancement platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1 ● Further strengthened leading intellectual property (“IP”) position with issuance of new patent in the United States and successful defense agai |
|
| November 7, 2023 |
Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position at September 30, 2023 and December 31, 2022 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three and Nine Month Periods ended September 30, 2023 and 2022 2 U |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 7, 2023 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Including Area Code |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Incl |
|
| September 27, 2023 |
ProQR Therapeutics Provides Update on Ophthalmic Assets Exhibit 99.1 ProQR Therapeutics Provides Update on Ophthalmic Assets LEIDEN, Netherlands & CAMBRIDGE, Mass., September 27, 2023 – ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previously announced agreement to divest the Company’s late-stage ophthalmic assets to Laboratoires Théa S.A.S. ( |
|
| September 14, 2023 |
PRQR / ProQR Therapeutics N.V / VAN HERK INVESTMENTS B.V. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ProQR Therapeutics N.V. (Name of Issuer) Ordinary Shares, nominal value €0.04 per share (Title of Class of Securities) N71542109 (CUSIP Number) September 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| September 14, 2023 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completene |
|
| August 3, 2023 |
Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position at June 30, 2023 and December 31, 2022 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three and Six Month Periods ended June 30, 2023 and 2022 1 Unaudited Co |
|
| August 3, 2023 |
Exhibit 99.2 ProQR Announces Second Quarter 2023 Operating and Financial Results ● Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline ● €129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., August 3, 2023 – |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 3, 2023 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Including Area Code, |
|
| August 1, 2023 |
Exhibit 99.1 ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on t |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includi |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Including |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 16, 2023 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Including Area Code, of |
|
| May 16, 2023 |
Attributable to owners of the Company Exhibit 99.2 ProQR Announces First Quarter 2023 Operating and Financial Results ● Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1 ● Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas ● Strength of intellectual property estate and leading IP position suppor |
|
| May 16, 2023 |
Attributable to owners of the Company Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position at March 31, 2023 and December 31, 2022 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three Month Periods ended March 31, 2023 and 2022 2 Unaudited Condense |
|
| April 24, 2023 |
Up to 13,371,562 Ordinary Shares TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-270943 PROSPECTUS Up to 13,371,562 Ordinary Shares This prospectus relates to the resale or other disposition, from time to time, of up to 13,371,562 of our ordinary shares, nominal value €0.04 per share (the “Shares”), by the selling shareholders identified in this prospectus (each a “Selling Shareholder” and collectively, |
|
| April 20, 2023 |
PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands VIA EDGAR AND FEDERAL EXPRESS April 20, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Arzhang Navai Re: ProQR Therapeutics N.V. Acceleration Request for Registration Statement on Form F-3 File No. 333-270943 Dear Arzhang Navai: Pursuant to |
|
| April 18, 2023 |
our Report of Foreign Private Issuer on Form 6-K filed with the SEC on April 18, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| April 18, 2023 |
Exhibit 99.2 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. Notice and Agenda ProQR Therapeutics N.V. | Zernikedreef 9 | 2333 CK Leiden | The Netherlands | +31 88 166 7000 | www.proqr.com Page 2 / 3 2023 Annual General Meeting of Shareholders ProQR Therapeutics N.V. - Notice and Agenda Notice for the AGM The 2023 annual general meeting of shareholders of ProQR Therapeutics N.V |
|
| April 18, 2023 |
Announces Annual Meeting of Shareholders to be Held May 17, 2023 Exhibit 99.1 ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2023 – ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will |
|
| April 18, 2023 |
POWER OF ATTORNEY AGM PROQR THERAPEUTICS N.V. MAY 17, 2023 Exhibit 99.4 POWER OF ATTORNEY AGM PROQR THERAPEUTICS N.V. MAY 17, 2023 Note: If you hold your shares through a bank, a financial institution, or other financial intermediary, you are considered a "beneficial owner" and you should follow the instructions and use the voting instrument provided by the bank or intermediary, financial institution, account holder or other financial intermediary that ho |
|
| April 18, 2023 |
Exhibit 99.3 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. Explanatory Notes to the Agenda ProQR Therapeutics N.V. | Zernikedreef 9 | 2333 CK Leiden | The Netherlands | +31 88 166 7000 | www.proqr.com Page 2 / 7 2023 Annual General Meeting of Shareholders ProQR Therapeutics N.V. - Explanatory Notes to the Agenda Explanatory notes to the agenda for the 2023 annual general meet |
|
| March 29, 2023 |
Exhibit 99.1 ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event ● Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025 ● Axiomer activity demonstrated across multiple preclinical in vitro, |
|
| March 29, 2023 |
ProQR Therapeutics N.V. Zernikedreef 9 2333 CK Leiden The Netherlands +31 88 166 7000 ProQR Therapeutics N.V. Zernikedreef 9 2333 CK Leiden The Netherlands +31 88 166 7000 March 29, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Re: ProQR Therapeutics N.V.– Request for Withdrawal of Registration Statement on Form F-3 (File No. 333-260780) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Sec |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF T |
|
| March 29, 2023 |
As filed with the Securities and Exchange Commission on March 29, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 29, 2023 Registration No. |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| March 29, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Daniel de Boer, certify that: 1. I have reviewed this annual report on Form 20-F of ProQR Therapeutics N.V. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the st |
|
| March 29, 2023 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-199451 and No. 333-260801 on Form S-8 and Registration Statement No. 333-260775, No. 333-263166 and No. 333-248740 on Form F-3 of our report dated March 24, 2021, relating to the financial statements of ProQR Therapeutics N.V., appearing in this Annua |
|
| March 29, 2023 |
Consent of Deloitte Accountants B.V., Independent Registered Public Accounting Firm Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the registration statements No.333-260801 and No. 333-199451 on Form S-8, and registration statements No. 333-263166, No. 333-260775, and No. 333-248740 on Form F-3 of our reports dated March 29, 2023, with respect to the consolidated financial statements of ProQR Therapeutics N.V. |
|
| March 29, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jurriaan Dekkers, certify that: 1. I have reviewed this annual report on Form 20-F of ProQR Therapeutics N.V. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| March 29, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) ProQR Therapeutics N. |
|
| March 29, 2023 |
Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 Of The Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Daniel de Boer, the Chief Executive Officer, and Jurriaan Dekkers, the Chief Financial Officer, of ProQR Therapeutics N.V. (the “Company”), hereby certify, that, |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| February 14, 2023 |
PRQR / ProQR Therapeutics N.V. / RTW INVESTMENTS, LP - PROQR THERAPEUTICS N.V. Passive Investment SC 13G/A 1 p23-0685sc13ga.htm PROQR THERAPEUTICS N.V. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* ProQR Therapeutics N.V. (Name of Issuer) Ordinary Shares, nominal value €0.04 per share (Title of Class of Securities) N71542109 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this state |
|
| February 9, 2023 |
SC 13G/A 1 p23-0698sc13ga.htm PROQR THERAPEUTICS N.V. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* ProQr Therapeutics N.V. (Name of Issuer) Ordinary Shares, nominal value €0.04 per share (Title of Class of Securities) N71542109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This State |
|
| February 9, 2023 |
PRQR / ProQR Therapeutics N.V. / Stichting Aescap 2.0 - SC 13G/A Passive Investment SC 13G/A 1 tm235875d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 19341 (Amendment No. 4)* ProQR Therapeutics N.V. (Name of Issuer) Ordinary Shares, nominal value €0.04 per share (Title of Class of Securities) N71542109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this State |
|
| February 9, 2023 |
EX-99.1 2 tm235875d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. Th |
|
| December 23, 2022 |
Exhibit 10.2 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is entered into as of December 21, 2022 (the “Execution Date”), by and between ProQR Therapeutics N.V., a public company with limited liability (naamloze vennootschap) incorporated under the laws of The Netherlands (“ProQR”), and Eli Lilly and Company, a corporation organized and existing under the laws of India |
|
| December 23, 2022 |
PRQR / ProQR Therapeutics N.V. / ELI LILLY & Co - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ProQR Therapeutics N.V. (Name of Issuer) Ordinary Shares, nominal value 0.04 EUR per share (Title of Class of Securities) N71542109 (CUSIP Number) December 21, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2022 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Inclu |
|
| December 23, 2022 |
Exhibit 99.2 For precision medicinesAXIOMER®RNA BASE EDITING TECHNOLOGY PLATFORM Ticker: PRQR December 22, 2022 WelcomeSarah KielyStrategic Overview, Lilly Partnership ExpansionDaniel de BoerAxiomer®RNA Editing Platform TechnologyGerard PlatenburgProQR Therapeutics -Partnership Expansion2Agenda Sarah KielyVP Investor Relations & Corporate Communications Daniel de BoerFounder & CEO Gerard Platenbur |
|
| December 23, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. AMENDED AND RESTATED RESEARCH AND COLLABORATION AGREEMENT by and among Eli Lilly and Company and ProQR Therapeutics N.V. and Pr |
|
| December 23, 2022 |
Exhibit 99.1 Lilly and ProQR to Expand RNA Editing Collaboration New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR’s Axiomer technology INDIANAPOLIS; LEIDEN, Netherlands; and CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) – Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 9, 2022 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Including Area Code |
|
| November 9, 2022 |
Attributable to owners of the Company Exhibit 99.2 ProQR Announces Third Quarter 2022 Operating and Financial Results ● Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023 ● Management Team appointments and planned additions to the Supervisory Board further strengthen le |
|
| November 9, 2022 |
Attributable to owners of the Company Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position at September 30, 2022 and December 31, 2021 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three and Nine Month Periods ended September 30, 2022 and 2021 2 U |
|
| September 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2022 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Incl |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2022 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includi |
|
| August 11, 2022 |
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs Exhibit 99.1 ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs ? In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer? RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023 ? Additional pivotal trial recommended by E |
|
| August 4, 2022 |
Attributable to owners of the Company Table of Contents Exhibit 99.1 ? PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements ? ? PAGE Unaudited Condensed Consolidated Statement of Financial Position at June 30, 2022 and December 31, 2021 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three and Six Month Periods ended June 30, 2022 and 2021 2 Unaudi |
|
| August 4, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 6-K ? Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 ? August 4, 2022 Commission File Number: 001-36622 ? PROQR THERAPEUTICS N.V. ? Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Includi |
|
| August 4, 2022 |
Attributable to owners of the Company ? Exhibit 99.2 ProQR Announces Second Quarter 2022 Operating and Financial Results ? ProQR is accelerating the development of its Axiomer? RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022 ? Company plans to discuss findings from sepofarsen Illuminate trial with regulators and provide an update in Q3/early Q4; Enrollment i |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2022 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Including |
|
| June 1, 2022 |
Exhibit 99.2 PAGE 1 / 4 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. - NOTICE AND AGENDA 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. - NOTICE AND AGENDA PROQR THERAPEUTICS I ZERNIKEDREEF 9 I 2333 CK LEIDEN I THE NETHERLANDS I +31 88 166 7000 I WWW.PROQR.COM PAGE 2 / 4 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. - NOTICE AND AGE |
|
| June 1, 2022 |
POWER OF ATTORNEY AGM PROQR THERAPEUTICS N.V. JUNE 30, 2022 Exhibit 99.4 POWER OF ATTORNEY AGM PROQR THERAPEUTICS N.V. JUNE 30, 2022 Note: If you hold your shares through a bank, a financial institution, or other financial intermediary, you are considered a "beneficial owner" and you should follow the instructions and use the voting instrument provided by the bank or intermediary, financial institution, account holder or other financial intermediary that h |
|
| June 1, 2022 |
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates Exhibit 99.1 ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates ? Annual General Meeting of Shareholders to be held on June 30, 2022 ? Ren? Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management Board ? Gerard Platenburg to assume Chief Scientific Officer role, with leadership oversight of Axiomer? |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2022 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Including |
|
| June 1, 2022 |
2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF PROQR THERAPEUTICS N.V. EXPLANATORY NOTES TO THE Exhibit 99.3 PAGE 1 / 11 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF PROQR THERAPEUTICS N.V. - EXPLANATORY NOTES 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF PROQR THERAPEUTICS N.V. - EXPLANATORY NOTES TO THE AGENDA PROQR THERAPEUTICS I ZERNIKEDREEF 9 I 2333 CK LEIDEN I THE NETHERLANDS I +31 88 166 7000 I WWW.PROQR.COM PAGE 2 / 11 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF PROQR THERAPEUT |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* ProQR Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) N71542109 (CUSIP Number) April 29, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| May 5, 2022 |
Attributable to owners of the Company ? Exhibit 99.2 ProQR Announces First Quarter 2022 Operating and Financial Results ? Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints ? Company plans to discuss findings with regulators and provide an update in Q3/early Q4 ? Enrollment is |
|
| May 5, 2022 |
Attributable to owners of the Company Table of Contents Exhibit 99.1 ? PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements ? ? PAGE Unaudited Condensed Consolidated Statement of Financial Position at March 31, 2022 and December 31, 2021 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three Month Periods ended March 31, 2022 and 2021 2 Unaudited Co |
|
| May 5, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 6-K ? Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 ? May 5, 2022 Commission File Number: 001-36622 ? PROQR THERAPEUTICS N.V. ? Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Including |
|
| April 29, 2022 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-15.2 7 tmb-20211231xex15d2.htm EX-15.2 Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-199451 and 333-260801 on Form S-8 and Registration Statement Nos. 333-260780, 333-260775, 333-263166 and 333-248740 on Form F-3 of our report dated March 24, 2021, relating to the financial statements of ProQ |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2022 |
Exhibit 12.1 ? Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 ? I, Daniel de Boer, certify that: ? 1. I have reviewed this annual report on Form 20-F of ProQR Therapeutics N.V. (the ?Company?); ? 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to mak |
|
| April 29, 2022 |
Consent of Deloitte Accountants B.V., Independent Registered Public Accounting Firm EX-15.1 6 tmb-20211231xex15d1.htm EX-15.1 Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the registration statements No. 333-260801 and No. 333-199451 on Form S-8,and Registration Statements No. 333-260780, No. 333-260775, No. 333-263166, and No. 333-248740 on Form F-3 of our reports dated April 29, 2022, with respect to the co |
|
| April 29, 2022 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Smital Shah, certify that: 1. I have reviewed this annual report on Form 20-F of ProQR Therapeutics N.V. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state |
|
| April 29, 2022 |
Exhibit 13.1 ? Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 Of The Sarbanes-Oxley Act of 2002 ? Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Daniel de Boer, the Chief Executive Officer, and Smital Shah, the Chief Business and Financial Officer, of ProQR Therapeutics N.V. (the ?Company?), hereby cer |
|
| April 13, 2022 |
Exhibit 99.1 STRATEGY UPDATE Nasdaq: PRQR Date: April 13, 2022 ProQR Therapeutics - Strategy Update 2 Agenda Intro Sarah Kiely Vice President Investor Relations and Corporate Communications Presentation Daniel A. de Boer Founder & CEO Q&A Daniel A. de Boer Founder & CEO Smital Shah Chief Business and Financial Officer Aniz Girach, MD Chief Medical Officer Gerard Platenburg Chief Innovation Officer |
|
| April 13, 2022 |
ProQR Announces Additional Sepofarsen Exhibit 99.1 ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy ? Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints ? Company plans to discuss findings with regulators in Q3 ? Illuminate |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2022 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2022 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| March 10, 2022 |
Up to 3,665,224 Ordinary Shares TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(5) ?Registration No. 333-263166? PROSPECTUS Up to 3,665,224 Ordinary Shares This prospectus relates to the resale or other disposition, from time to time, by the selling shareholders identified in this prospectus, and any of their respective donees, pledgees, transferees, or other successors-in-interest, of up to 3,665,224 of our ordinary shares, no |
|
| March 7, 2022 |
PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands VIA EDGAR AND FEDERAL EXPRESS March 7, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Michael Davis Re: ProQR Therapeutics N.V. Acceleration Request for Registration Statement on Form F-3 File No. 333- 263166 Dear Mr. Davis: Pursuant to Rul |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) ProQR Therapeutics N. |
|
| February 24, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 6-K ? Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 ? February 24, 2022 Commission File Number: 001-36622 ? PROQR THERAPEUTICS N.V. ? Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Incl |
|
| February 24, 2022 |
Attributable to owners of the Company Table of Contents Exhibit 99.1 ? PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements ? ? PAGE Unaudited Condensed Consolidated Statement of Financial Position at December 31, 2021 and December 31, 2020 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three Month Periods and the Years ended December 31, 2021 and |
|
| February 24, 2022 |
Attributable to owners of the Company ? ? Exhibit 99.2 ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results ? Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022 ? Phase 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and retinitis pigmentosa |
|
| February 14, 2022 |
PRQR / ProQR Therapeutics N.V. / RTW INVESTMENTS, LP - PROQR THERAPEUTICS N.V. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* ProQR Therapeutics N.V. (Name of Issuer) Ordinary Shares, nominal value ?0.04 per share (Title of Class of Securities) N71542109 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2022 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Inclu |
|
| February 11, 2022 |
ProQR Announces Top-Line Results from Phase 2/3 Exhibit 99.1 ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10 ? Study did not meet primary endpoint nor notable secondary endpoints ? no benefit observed in either treatment arm versus sham ? Additional analyses to be conducted and presented at a future medical congress ? Sepofarsen continues to be generally well tolerated ? Strong cash positi |
|
| February 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* ProQr Therapeutics N.V. (Name of Issuer) Ordinary Shares, nominal value €0.04 per share (Title of Class of Securities) N71542109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ProQR Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) N71542109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 4, 2022 |
PRQR / ProQR Therapeutics N.V. / Stichting Aescap 2.0 - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 19341 (Amendment No. 3)* ProQR Therapeutics N.V. (Name of Issuer) Ordinary Shares, nominal value ?0.04 per share (Title of Class of Securities) N71542109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| January 4, 2022 |
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Exhibit 99.1 ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen ? Top-line data now expected to be announced in Q1 2022 ? Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands & CAMBRIDGE, Mass., January 4, 2022 - ProQR Therapeutics N.V. (Nasda |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2022 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includ |
|
| December 30, 2021 |
Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT, dated as of December 29, 2021 (this ?Amendment?), is entered into by and among ProQR Therapeutics N.V., a company incorporated in the Netherlands, ProQR Therapeutics Holding B.V., a company incorporated in the Netherlands and each of their Subsidiaries party hereto (collectively referre |
|
| December 30, 2021 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of December 29, 2021 by and among ProQR Therapeutics N.V., a company incorporated in the Netherlands (the ?Company?), the ?Pontifax Lenders? and the ?Kreos Warrant Holders? identified in Schedule A attached hereto. Capitalized terms used herein have the respective meanings a |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Inclu |
|
| December 30, 2021 |
Exhibit 99.1 ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital LEIDEN, Netherlands & CAMBRIDGE, Mass., December 30, 2021 (GLOBE NEWSWIRE) - ProQR Therapeutics N.V. (Nasdaq:PRQR) (?ProQR?), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that it has amended i |
|
| December 30, 2021 |
Exhibit 10.4 ORDINARY SHARES PURCHASE WARRANT ProQR Therapeutics N.V. Warrant Shares: [] THIS ORDINARY SHARES PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, [] or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time prior to the close of business on the fifth-year anniversary of |
|
| December 30, 2021 |
Exhibit 10.2 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of July 14, 2020 and is entered into by and among ProQR Therapeutics N.V., a company incorporated in the Netherlands, ProQR Therapeutics Holding B.V., a company incorporated in the Netherlands and each of their Subsidiaries from time to time party hereto (collectively referred to as ?Borrower? or ?ProQR? |
|
| December 16, 2021 |
Exhibit 99.1 ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A mediated Retinitis Pigmentosa LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) - ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed i |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Inclu |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Inclu |
|
| November 18, 2021 |
ProQR Announces Highlights from Analyst Event Exhibit 99.1 ProQR Announces Highlights from Analyst Event LEIDEN, Netherlands & CAMBRIDGE, Mass., November 18, 2021 - ProQR Therapeutics N.V. (Nasdaq: PRQR) (the ?Company?), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event. Management provided an in-depth review of the Company?s clinical-stage |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Inclu |
|
| November 18, 2021 |
Exhibit 99.1 PROQR ANALYST EVENT November 18, 2021 Forward looking statements ProQR Therapeutics - Analyst Event 2021 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including but not limited to, statements regarding our strategy, future operations, f |
|
| November 17, 2021 |
Up to $75,000,000 Ordinary Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-260775 PROSPECTUS Up to $75,000,000 Ordinary Shares We have entered into a Controlled Equity OfferingSM Sales Agreement (the “sales agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald” or the “Agent”), relating to the sale of our ordinary shares, nominal value €0.04 per share, offered by this prospectus. In accor |
|
| November 17, 2021 |
Up to 3,989,976 Ordinary Shares TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(5)? ?Registration no. 333-260780? PROSPECTUS Up to 3,989,976 Ordinary Shares ? This prospectus relates to the resale or other disposition, from time to time, of up to 3,989,976 of our ordinary shares, nominal value ?0.04 per share (the ?Shares?), by the selling shareholders identified in this prospectus (each a ?Selling Shareholder? and collectively |
|
| November 12, 2021 |
PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands CORRESP 1 filename1.htm PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands VIA EDGAR November 12, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Christine Westbrook Re: ProQR Therapeutics N.V. Acceleration Request for Registration Statement on Form F-3 Filed November 4, 2021 File No. 333-26 |
|
| November 4, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 4, 2021 Registration No. |
|
| November 4, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 4, 2021 Registration No. |
|
| November 4, 2021 |
Attributable to owners of the Company Exhibit 99.2 ProQR Announces third Quarter 2021 Operating and Financial Results ● Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022 ● Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing platform and strengthens financial position with $50 million in upfront and equit |
|
| November 4, 2021 |
Attributable to owners of the Company Table of Contents Exhibit 99.1 ? PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements ? ? PAGE Unaudited Condensed Consolidated Statement of Financial Position at September 30, 2021 and December 31, 2020 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three and Nine Month Periods ended September 30, 2021 and 20 |
|
| November 4, 2021 |
Exhibit 1.2 ProQR Therapeutics N.V. Ordinary Shares (nominal value ?0.04 per share) Sales Agreement November 4, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: ProQR Therapeutics N.V., a Dutch public company with limited liability (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1. Issuance and |
|
| November 4, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 6-K ? Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 ? November 4, 2021 Commission File Number: 001-36622 ? PROQR THERAPEUTICS N.V. ? Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Inclu |
|
| November 4, 2021 |
Exhibit 5.3 To ProQR Therapeutics N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Allen & Overy LLP Apollolaan 15 1077 AB Amsterdam The Netherlands PO Box 75440 1070 AK Amsterdam The Netherlands Tel +31 20 674 1000 Fax +31 20 674 1111 Amsterdam, 4 November 2021 Subject 5.3 Dutch law legal opinion Dear Sirs, Madam, 1. We have acted as legal counsel to you, ProQR Therapeutics N.V., a public limit |
|
| November 4, 2021 |
As filed with the U.S. Securities and Exchange Commission on November 4, 2021 As filed with the U.S. Securities and Exchange Commission on November 4, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROQR THERAPEUTICS N.V. (Exact name of registrant as specified in its charter) The Netherlands Not applicable (State or other jurisdiction of incorporation or orga |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includ |
|
| October 4, 2021 |
ProQR Appoints Theresa Heggie as Chief Commercial Officer Exhibit 99.1 ProQR Appoints Theresa Heggie as Chief Commercial Officer ? Senior leader with extensive global rare disease commercialization experience ? Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 LEIDEN, Netherlands & CAMBRIDGE, Mass., October 4, 2021 ? ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to cha |
|
| September 10, 2021 |
PRQR / ProQR Therapeutics N.V. / ELI LILLY & Co - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ProQR Therapeutics N.V. (Name of Issuer) Ordinary Shares, nominal value 0.04 EUR per share (Title of Class of Securities) N71542109 (CUSIP Number) September 3, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Incl |
|
| September 9, 2021 |
Presentation for webcasted conference call Exhibit 99.1 |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Incl |
|
| September 8, 2021 |
Exhibit 10.2 EXECUTION VERSION SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this ?Agreement?) is entered into as of September 3, 2021 (the ?Execution Date?), by and between ProQR Therapeutics N.V., a public company with limited liability (naamloze vennootschap) incorporated under the laws of The Netherlands (?ProQR?), and Eli Lilly and Company, a corporation organized and existing under |
|
| September 8, 2021 |
Exhibit 99.1 ProQR Announces Axiomer? RNA Editing Licensing and Research Collaboration with Lilly ? Companies will collaborate to develop editing oligonucleotides directed to up to five targets using ProQR?s proprietary Axiomer? RNA editing platform ? ProQR to receive $50 million consisting of upfront payment and equity investment ? ProQR is eligible to additionally receive up to approximately $1. |
|
| September 8, 2021 |
Exhibit 10.1 Certain information identified by [***] have been excluded from this exhibit because it is both (i) not material and (ii) competitively harmful if publicly disclosed. EXECUTION VERSION RESEARCH AND COLLABORATION AGREEMENT by and among Eli Lilly and Company and ProQR Therapeutics N.V. and ProQR Therapeutics VIII B.V. CONFIDENTIAL RESEARCH AND COLLABORATION AGREEMENT This Research and C |
|
| August 5, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 6-K ? Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 ? August 5, 2021 Commission File Number: 001-36622 ? PROQR THERAPEUTICS N.V. ? Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Includi |
|
| August 5, 2021 |
Attributable to owners of the Company ? ? Exhibit 99.2 ProQR Announces second Quarter 2021 Operating and Financial Results ? Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 ? QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher syndrome and retinitis pigmentosa expected to start by year end 2021 ? Initial clinical data from Phase 1/2 Aurora trial of QR-1123 for |
|
| August 5, 2021 |
Attributable to owners of the Company Table of Contents Exhibit 99.1 ? PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements ? ? PAGE Unaudited Condensed Consolidated Statement of Financial Position at June 30, 2021 and December 31, 2021 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three and Six Month Periods ended June 30, 2021 and 2020 2 Unaudi |
|
| July 8, 2021 |
Exhibit 1.1 ARTICLES OF ASSOCIATION OF: ProQR Therapeutics N.V. having its official seat in Leiden, the Netherlands, as per 10 June 2021. CONTENTS: A fair English translation of the complete text of the articles of association of ProQR Therapeutics N.V., as they read after amendment, executed by notarial deed on 10 June 2021 before S.C. Roozendaal, civil law notary in Amsterdam, the Netherlands. I |
|
| July 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Including |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Including |
|
| May 6, 2021 |
Current Report of Foreign Issuer - 6-K ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 6-K ? Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 ? May 6, 2021 Commission File Number: 001-36622 ? PROQR THERAPEUTICS N.V. ? Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including ZIP Code, and Telephone Number, Including |
|
| May 6, 2021 |
Attributable to owners of the Company ? ? Exhibit 99.2 ProQR Announces First Quarter 2021 Operating and Financial Results ? Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022 ? Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retinitis pigmentosa, with plans to advance the program into two pivo |
|
| May 6, 2021 |
Attributable to owners of the Company Table of Contents Exhibit 99.1 ? PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements ? ? PAGE Unaudited Condensed Consolidated Statement of Financial Position at March 31, 2021 and March 31, 2020 1 Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Three-Month Periods ended March 31, 2021 and 2020 2 Unaudited Conde |
|
| May 4, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Including |
|
| May 4, 2021 |
Exhibit 99.1 ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target ? Yarrow Biotechnology, Inc., a newly formed biotechnology company backed by RTW Investments, LP, will lead development of the program ? ProQR Therapeutics is eligible to receive upfront and milestone payments of |
|
| April 20, 2021 |
2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. – NOTICE AND AGENDA Exhibit 99.2 PAGE 1 / 4 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. ? NOTICE AND AGENDA 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF PROQR THERAPEUTICS N.V. - NOTICE AND AGENDA PAGE 2 / 4 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF PROQR THERAPEUTICS N.V. ? NOTICE AND AGENDA Notice for the AGM The 2021 annual general meeting of shareholders of ProQR Therapeutics N.V. ( |
|
| April 20, 2021 |
ProQR Announces Annual Meeting of Shareholders Exhibit 99.1 ProQR Announces Annual Meeting of Shareholders LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2021 - ProQR Therapeutics N.V. (Nasdaq: PRQR) (the ?Company?), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the Annual General Meeting of Shareholders will take place on Wednesday, May 19, |
|
| April 20, 2021 |
POWER OF ATTORNEY AGM PROQR THERAPEUTICS N.V. MAY 19, 2021 Exhibit 99.4 POWER OF ATTORNEY AGM PROQR THERAPEUTICS N.V. MAY 19, 2021 Note: If you hold your shares through a bank, a financial institution, or other financial intermediary, you are considered a "beneficial owner" and you should follow the instructions and use the voting instrument provided by the bank or intermediary, financial institution, account holder or other financial intermediary that ho |
|
| April 20, 2021 |
2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF PROQR THERAPEUTICS N.V. – EXPLANATORY NOTES Exhibit 99.3 PAGE 1/ 7 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF PROQR THERAPEUTICS N.V. ? EXPLANATORY NOTES 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF PROQR THERAPEUTICS N.V. - EXPLANATORY NOTES TO THE AGENDA PROQR THERAPEUTICS | ZERNIKEDREEF 9 | 2333 CK LEIDEN | THE NETHERLANDS | +31 88 166 7000 | WWW.PROQR.COM PAGE 2/ 7 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF PROQR THERAPEUTICS |
|
| April 20, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| April 6, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| April 6, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| April 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 6, 2021 |
Consent of Deloitte Accountants B.V., Independent Registered Public Accounting Firm Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Supervisory Board and Shareholders of ProQR Therapeutics N.V. We consent to the incorporation by reference in Registration Statement No. 333-199451 on Form S-8 and Registration Statement Nos. 333-228251 and 333-248740 on Form F-3 of our reports dated March 24, 2021 relating to the financial statements of ProQR Therapeutic |
|
| April 1, 2021 |
ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares Exhibit 99.1 ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 - ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the pricing of its previously announced underwritten public offering |
|
| April 1, 2021 |
13,846,154 Shares PROQR THERAPEUTICS N.V. Ordinary Shares Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| April 1, 2021 |
13,846,154 Shares PROQR THERAPEUTICS N.V. Ordinary Shares Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| April 1, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2021 Commission File Number: 001-36622 PROQR THERAPEUTICS N.V. Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address, Including Zip Code, and Telephone Number, Includin |
|
| April 1, 2021 |
Exhibit 1.1 ProQR Therapeutics N.V. 13,846,154 Ordinary Shares UNDERWRITING AGREEMENT Dated: March 30, 2021 ProQR Therapeutics N.V. 13,846,154 Ordinary Shares UNDERWRITING AGREEMENT March 30, 2021 Citigroup Global Markets Inc. Evercore Group L.L.C. As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Evercore Group L.L. |
|
| March 30, 2021 |
SUBJECT TO COMPLETION, DATED MARCH 30, 2021 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| March 24, 2021 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Daniel de Boer, certify that: 1. I have reviewed this annual report on Form 20-F of ProQR Therapeutics N.V. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the st |
|
| March 24, 2021 |
Exhibit 13.1 ? Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 Of The Sarbanes-Oxley Act of 2002 ? Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Daniel de Boer, the Chief Executive Officer, and Smital Shah, the Chief Business and Financial Officer, of ProQR Therapeutics N.V. (the ?Company?), hereby cer |
|
| March 24, 2021 |
Letter from Deloitte Accountants B.V. regarding change in Registrant’s certifying accountant Exhibit 16.1 ? ? ? ? ? ? ? ? March 24, 2021 ? U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 ? ? Dear Sirs/Madams: ? We have read Item 16F of Form 20-F of ProQR Therapeutics N.V. for the year ended December 31, 2020 to be filed on or around March 24, 2021 and have the following comments: ? 1. We agree with the statements made in the second, third and fourth |
